Suggested remit - To appraise the clinical and cost effectiveness of carfilzomib with daratumumab and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma.
Status In progress
Process STA 2018
ID number 2709

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
18 May 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma. For information, this appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that this drug will consequently not be eligible to receive interim CDF funding from the date of marketing authorisation as no NICE recommendation will be made at that point. For information, this appraisal is now anticipated to begin during mid-May 2021 when we will write to you about how you can get involved.
02 March 2020 - 30 March 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 January 2020 In progress. Referred September 23 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance